about
Enterotypes of the human gut microbiomeUnstable composition of the fecal microbiota in ulcerative colitis during clinical remission.Contribution of nurses to the quality of care in management of inflammatory bowel disease: a synthesis of the evidence.Influence of colectomy on hydrogen excretion in breath.Nursing resources and responsibilities according to hospital organizational model for management of inflammatory bowel disease in Spain.Questionnaries for measuring fatigue and its impact on health perception in inflammatory bowel disease.Inflammatory bowel disease patient's satisfaction with healthcare services received. Physicians' and nurses' perceptions.Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units.Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFα treatment.Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life.[Application of a model of continued attention in inflammatory bowel disease: the Crohn-colitis care unit].Fecal excretion of deoxyribonucleic acid in long-term follow-up of patients with inactive ulcerative colitis.Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectinSatisfaction of health care professionals managing patients with inflammatory bowel diseaseValidation of the Spanish version of a questionnaire to measure quality of care through the eyes of patients with inflammatory bowel disease (QUOTE-IBD)Use of Health Apps by Nurses for Professional Purposes: Web-Based Survey StudyCorrection: Use of Health Apps by Nurses for Professional Purposes: Web-Based Survey Study
P50
Q24489818-ED06027D-47CD-4BA4-A84B-B328B46477D5Q33323929-B0CDEC1A-9947-42AF-9348-67647602DB40Q33760094-C7117B55-0E7F-4EFF-A187-442577753CCEQ43245150-C0BFBC28-C60E-4B03-920F-7D228BC5B746Q43903173-5DF79A5E-6104-4C26-A214-0693362BC701Q44032467-484453F7-855B-4BBA-B834-9094E3E3DE01Q44064617-8B012B03-0923-4FA3-AE3F-900DE0AD7B1FQ44987300-D4C90E45-9AB2-43A8-88F0-D799298A891DQ48471638-89FC81E2-5EF8-48E0-9B1F-2DA8E9A07031Q48739362-B7FFC75F-07E4-4300-A431-A414EB1C93CCQ50617956-6A76E8DB-2434-44EA-9DAC-1AE0241C0512Q54563936-FC50EEA3-A84B-428A-AA5A-57A625C420CCQ57241178-579C3B94-A5BC-4AE9-8AE3-59387C61CC8BQ61960998-D0082D19-06BF-476C-80B4-69D61D8E233DQ61961000-3813C28B-1C66-4B3E-B295-3DC1E3D32C88Q91089144-94E9B8EE-E9CD-4177-9F64-4F6EEEE38E6AQ94468214-B915B368-E095-416D-A42B-895F745032B5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonio Torrejon
@ast
Antonio Torrejon
@en
Antonio Torrejon
@es
Antonio Torrejon
@nl
type
label
Antonio Torrejon
@ast
Antonio Torrejon
@en
Antonio Torrejon
@es
Antonio Torrejon
@nl
prefLabel
Antonio Torrejon
@ast
Antonio Torrejon
@en
Antonio Torrejon
@es
Antonio Torrejon
@nl
P106
P1153
23981349400
P21
P31
P496
0000-0002-3126-1532